ERBB2 and ductal breast carcinoma in situ: The LORETTA trial (opened 2017) in Japan [22] includes patients with similar features to the other three clinical trials of active surveillance; eligible patients have low or intermediate-grade DCIS with no comedo-type necrosis, but inclusion criteria also include ER positivity and HER2 negativity.